UM1TR005449
Cooperative Agreement
Overview
Grant Description
Ctsa Um1 program at University of California San Diego Altman Clinical and Translational Research Institute - Project summary
The Altman Clinical and Translational Research Institute (ACTRI) at the University of California San Diego (UCSD) dynamically and rapidly translates scientific discoveries into innovative health solutions.
Given the significant growth of our biomedical research portfolio during the last funding cycle, we are positioned to grow our profound impact on advancing translational science and public health within our region and beyond.
To amplify our efforts, we will leverage our culture of team science to discover, develop, and catalyze clinical and translational science (CTS) innovations, determine their efficacy and effectiveness, and disseminate and implement these inventions to overcome roadblocks in translation.
Examples of innovative activities that we are excited about include: a new Inclusion, Diversity, Equity, and Accessibility (IDEA) committee that assesses the ACTRI efforts through a lens of inclusivity (Element B), a robust workforce development portfolio that tackles key challenges faced by CTS researchers across the continuum of their careers, including capacity-building for future leaders with our Leadership Academy (Module C1 and K12); the use of a community-centric approach to build trust and expand the reach of our research (Module C2); the use of artificial intelligence in CTS research and a new next-gen trial team to help investigators design and execute decentralized, platform, and adaptive trials (Modules D1, D3); the development of a What’s Next? program to assist early-stage investigators who receive pilot project grants and other ACTRI services in their career planning (Module D2); and new methods for sampling the immune milieu in the upper respiratory tract, use of serious games for developing team science and systems thinking, and finding best ways to provide naloxone to stop overdose deaths in local tribal lands (Element E).
To leverage our expertise and avoid over-extending our resources, we have strategically established partnerships.
Our biomedical science partners (i.e., Salk Institute, Sanford Burnham Prebys, and La Jolla Institute for Immunology) provide considerable depth in basic science discoveries that require further translation to improve health.
Our clinical partners serve vulnerable and underserved populations in our rural and border regions (i.e., El Centro Regional Medical Center, Eisenhower Health), children and adolescents (i.e., Rady Children’s Hospital), and military veterans (i.e., Veterans Affairs San Diego Healthcare System).
Our new higher education partner, Mesa College of the San Diego Community College District, has a superb track record for serving under-represented students.
In forging these strategic alliances and embracing a culture of inclusive innovation, the ACTRI is not just advancing CTS, it is ensuring impact, and fostering a diverse, sustainable workforce that will drive groundbreaking health solutions for future generations.
The Altman Clinical and Translational Research Institute (ACTRI) at the University of California San Diego (UCSD) dynamically and rapidly translates scientific discoveries into innovative health solutions.
Given the significant growth of our biomedical research portfolio during the last funding cycle, we are positioned to grow our profound impact on advancing translational science and public health within our region and beyond.
To amplify our efforts, we will leverage our culture of team science to discover, develop, and catalyze clinical and translational science (CTS) innovations, determine their efficacy and effectiveness, and disseminate and implement these inventions to overcome roadblocks in translation.
Examples of innovative activities that we are excited about include: a new Inclusion, Diversity, Equity, and Accessibility (IDEA) committee that assesses the ACTRI efforts through a lens of inclusivity (Element B), a robust workforce development portfolio that tackles key challenges faced by CTS researchers across the continuum of their careers, including capacity-building for future leaders with our Leadership Academy (Module C1 and K12); the use of a community-centric approach to build trust and expand the reach of our research (Module C2); the use of artificial intelligence in CTS research and a new next-gen trial team to help investigators design and execute decentralized, platform, and adaptive trials (Modules D1, D3); the development of a What’s Next? program to assist early-stage investigators who receive pilot project grants and other ACTRI services in their career planning (Module D2); and new methods for sampling the immune milieu in the upper respiratory tract, use of serious games for developing team science and systems thinking, and finding best ways to provide naloxone to stop overdose deaths in local tribal lands (Element E).
To leverage our expertise and avoid over-extending our resources, we have strategically established partnerships.
Our biomedical science partners (i.e., Salk Institute, Sanford Burnham Prebys, and La Jolla Institute for Immunology) provide considerable depth in basic science discoveries that require further translation to improve health.
Our clinical partners serve vulnerable and underserved populations in our rural and border regions (i.e., El Centro Regional Medical Center, Eisenhower Health), children and adolescents (i.e., Rady Children’s Hospital), and military veterans (i.e., Veterans Affairs San Diego Healthcare System).
Our new higher education partner, Mesa College of the San Diego Community College District, has a superb track record for serving under-represented students.
In forging these strategic alliances and embracing a culture of inclusive innovation, the ACTRI is not just advancing CTS, it is ensuring impact, and fostering a diverse, sustainable workforce that will drive groundbreaking health solutions for future generations.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
California
United States
Geographic Scope
State-Wide
San Diego University Of California was awarded
UCSD ACTRI: Advancing Clinical Translational Science
Cooperative Agreement UM1TR005449
worth $10,325,540
from National Center for Advancing Translational Sciences in August 2025 with work to be completed primarily in California United States.
The grant
has a duration of 6 years 8 months and
was awarded through assistance program 93.350 National Center for Advancing Translational Sciences.
The Cooperative Agreement was awarded through grant opportunity Clinical and Translational Science Award (UM1 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 8/20/25
Period of Performance
8/1/25
Start Date
4/30/32
End Date
Funding Split
$10.3M
Federal Obligation
$0.0
Non-Federal Obligation
$10.3M
Total Obligated
Activity Timeline
Transaction History
Modifications to UM1TR005449
Additional Detail
Award ID FAIN
UM1TR005449
SAI Number
UM1TR005449-569346444
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NR00 NIH National Center for Advancing Translational Sciences
Funding Office
75NR00 NIH National Center for Advancing Translational Sciences
Awardee UEI
UYTTZT6G9DT1
Awardee CAGE
50854
Performance District
CA-90
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Modified: 8/20/25